MAPT and Alzheimer disease: Gosuranemab was derived from IPN002, a murine IgG1 monoclonal antibody and binds with high affinity to N-terminal tau secreted from Alzheimer’s disease (AD) patient-derived cortical neurons resulting in reduced neuronal hyperactivity [6].